This article from Forbes reports on a new venture capital fund started by three former executives of Millennium Pharmaceuticals: Mark Levin, Kevin Starr, and Bob Tepper. They just raised $378 million for what they're calling Third Rock Ventures. According to the article, the fund will be closely managing startup companies, and will "only look at a few biotechs, each getting a few tens of millions of dollars."

 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.